CelLBxHealth has announced a research collaboration with The Royal Marsden NHS Foundation Trust, one of the world’s leading cancer centres, to evaluate the clinical utility of its CTC‑DNA technology in blood samples from patients with advanced lung cancer. The study targets a clearly defined and underserved patient cohort, those with uninformative ctDNA results, and represents an important validation step for CelLBxHealth’s proposition that CTC‑derived DNA can provide additional, actionable geno ....
